International ClinicsMedical News
International Clinics Newsroom · · 1 min read
Daily

FDA approves tucatinib as chemotherapy-free maintenance for advanced HER2-positive breast cancer

  • On 7 October 2026 the FDA approved Tukysa (tucatinib) with trastuzumab and pertuzumab as maintenance for advanced HER2-positive breast cancer.
  • Tucatinib maintenance starts after induction treatment that includes chemotherapy.
  • In HER2CLIMB-05, median progression-free survival was 24.9 months with tucatinib versus 16.3 months with placebo.
  • Tucatinib carries a boxed warning for liver toxicity, and diarrhoea affected 73% of patients.
An oncologist holds the hand of a woman with breast cancer during a consultation
An oncologist holds the hand of a woman with breast cancer during a consultation Photo: AI-generated image (Gemini)
Published:

The US Food and Drug Administration approved Tukysa (tucatinib), from Pfizer subsidiary Seagen, on 7 October 2026 in combination with trastuzumab and pertuzumab as maintenance treatment for adults with unresectable locally advanced or metastatic HER2-positive breast cancer following induction treatment.

The trial

Approval rests on HER2CLIMB-05, a randomized double-blind trial of 654 patients whose disease had not progressed after 4–8 cycles of trastuzumab, pertuzumab and a taxane, including patients with brain metastases. They received tucatinib 300 mg or placebo twice daily with the two antibodies, without chemotherapy.

Also read: Breast Cancer Awareness Month: WHO launches training manual to expand early breast cancer care

Results

Median progression-free survival was 24.9 months with tucatinib versus 16.3 months with placebo, a 36% lower risk of progression or death. Overall survival data are immature, and progression was assessed by investigators.

Safety

Tucatinib carries a boxed warning for hepatotoxicity; one patient died of drug-induced liver injury. Liver tests are needed every 2 weeks for the first 2 months, then every 3 weeks. Diarrhoea occurred in 73% of patients, severe (grade 3) in 6%.

Sources: US Food and Drug Administration (FDA), AJMC, CURE

This story is relayed from the source named above; responsibility for its content rests with the original source.

FAQ

What did the FDA approve for tucatinib?

On 7 October 2026 the FDA approved tucatinib (Tukysa) with trastuzumab and pertuzumab as maintenance for advanced HER2-positive breast cancer after induction treatment.

What does tucatinib maintenance mean?

Tucatinib maintenance is given after chemotherapy-based induction ends, to keep HER2-positive breast cancer under control longer without chemotherapy.

How long did tucatinib keep the disease in check?

In HER2CLIMB-05, median progression-free survival was 24.9 months with tucatinib versus 16.3 months with placebo.

What are the main risks of tucatinib?

Tucatinib has a boxed warning for liver toxicity, which can be fatal, so liver tests are needed regularly; it also often causes diarrhoea.

Does tucatinib maintenance extend overall survival?

The effect of tucatinib maintenance on overall survival is not yet known because HER2CLIMB-05 survival data are still immature.

How would you rate this story?
4,420
Latest news
A fluoride-free gel that may rebuild tooth enamel, from the University of Nottingham Jackson 5's Marlon Jackson reveals he has lived with prostate cancer for four years Tip of the day: get your flu vaccine early, before winter peaks Every plant-based food in a UK study contained fungal toxins, all within EU guideline levels Tip of the day: spit, don't rinse, after brushing your teeth Energy drinks appear 11 times more often in cardiac arrest reports, preliminary study finds ISAPS global survey: eyelid surgery leads, breast lift grows fastest and filler declines Hippocrates: "Life is short, and Art long" Born on this day: William Beaumont and the hole in a stomach that rewrote digestion Tip of the day: sleep at least 7 hours a night, on a regular schedule
The latest-news bar is closed. You can bring it back any time with the “Latest news” button in the menu.